Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 59

Cited In for PubMed (Select 15381934)

1.

The construct of breast cancer risk perception: need for a better risk communication?

de Jonge ET, Vlasselaer J, Van de Putte G, Schobbens JC.

Facts Views Vis Obgyn. 2009;1(2):122-9. Review.

2.

Breast Cancer Risk - Genes, Environment and Clinics.

Fasching PA, Ekici AB, Adamietz BR, Wachter DL, Hein A, Bayer CM, Häberle L, Loehberg CR, Jud SM, Heusinger K, Rübner M, Rauh C, Bani MR, Lux MP, Schulz-Wendtland R, Hartmann A, Beckmann MW.

Geburtshilfe Frauenheilkd. 2011 Dec;71(12):1056-1066.

3.

Breast cancer risk assessment using genetic variants and risk factors in a Singapore Chinese population.

Lee CP, Irwanto A, Salim A, Yuan JM, Liu J, Koh WP, Hartman M.

Breast Cancer Res. 2014 Jun 18;16(3):R64. doi: 10.1186/bcr3678.

4.

Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis.

Fasching PA, Ekici AB, Wachter DL, Hein A, Bayer CM, Häberle L, Loehberg CR, Schneider M, Jud SM, Heusinger K, Rübner M, Rauh C, Bani MR, Lux MP, Schulz-Wendtland R, Hartmann A, Beckmann MW.

Geburtshilfe Frauenheilkd. 2013 Dec;73(12):1228-1235.

5.

Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer.

Kim H, Choi DH.

J Breast Cancer. 2013 Dec;16(4):357-65. doi: 10.4048/jbc.2013.16.4.357. Epub 2013 Dec 31. Review.

6.

BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.

Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2; Breast Cancer Association Consortium.

Br J Cancer. 2014 Jan 21;110(2):535-45. doi: 10.1038/bjc.2013.730. Epub 2013 Dec 17.

7.

Hereditary cancer risk assessment: essential tools for a better approach.

Gomy I, Estevez Diz Mdel P.

Hered Cancer Clin Pract. 2013 Oct 28;11(1):16. doi: 10.1186/1897-4287-11-16.

8.

The korean hereditary breast cancer study: review and future perspectives.

Kang E, Kim SW.

J Breast Cancer. 2013 Sep;16(3):245-53. doi: 10.4048/jbc.2013.16.3.245. Epub 2013 Sep 30. Review.

9.

Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre.

MacInnis RJ, Bickerstaffe A, Apicella C, Dite GS, Dowty JG, Aujard K, Phillips KA, Weideman P, Lee A, Terry MB, Giles GG, Southey MC, Antoniou AC, Hopper JL.

Br J Cancer. 2013 Sep 3;109(5):1296-301. doi: 10.1038/bjc.2013.382. Epub 2013 Aug 13.

10.

Breast cancer in the young: role of the geneticist.

Woodson AH, Profato JL, Muse KI, Litton JK.

J Thorac Dis. 2013 Jun;5 Suppl 1:S19-26. doi: 10.3978/j.issn.2072-1439.2013.04.13.

11.

Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress.

Culver JO, Brinkerhoff CD, Clague J, Yang K, Singh KE, Sand SR, Weitzel JN.

Clin Genet. 2013 Nov;84(5):464-72. doi: 10.1111/cge.12097. Epub 2013 Feb 20.

12.

Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.

Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C, Jungbluth C, Cina C, Duncan P, Unzeitig G, Saldivar JS, Beattie M, Feldman N, Sand S, Port D, Barragan DI, John EM, Neuhausen SL, Larson GP.

J Clin Oncol. 2013 Jan 10;31(2):210-6. doi: 10.1200/JCO.2011.41.0027. Epub 2012 Dec 10. Erratum in: J Clin Oncol. 2013 May 1;31(13):1702.

13.

The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers.

Mazzola E, Cheng SC, Parmigiani G.

Breast Cancer Res Treat. 2013 Jan;137(1):315-8. doi: 10.1007/s10549-012-2345-5. Epub 2012 Nov 27.

14.

A focus group study on breast cancer risk presentation: one format does not fit all.

Dorval M, Bouchard K, Chiquette J, Glendon G, Maugard CM, Dubuisson W, Panchal S, Simard J.

Eur J Hum Genet. 2013 Jul;21(7):719-24. doi: 10.1038/ejhg.2012.248. Epub 2012 Nov 21.

15.

Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance.

Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB.

Breast Cancer Res. 2012 Nov 5;14(6):R144. doi: 10.1186/bcr3352.

16.

Sequence Variants of BRCA1 and BRCA2 Genes in Four Iranian Families with Breast and Ovarian Cancer.

Keshavarzi F, Noughani AE, Ayoubian M, Zeinali S.

Iran J Public Health. 2011;40(2):57-66. Epub 2011 Jun 30.

17.

BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.

Spurdle AB, Whiley PJ, Thompson B, Feng B, Healey S, Brown MA, Pettigrew C; kConFab, Van Asperen CJ, Ausems MG, Kattentidt-Mouravieva AA, van den Ouweland AM; Dutch Belgium UV Consortium, Lindblom A, Pigg MH, Schmutzler RK, Engel C, Meindl A; German Consortium of Hereditary Breast and Ovarian Cancer, Caputo S, Sinilnikova OM, Lidereau R; French COVAR group collaborators, Couch FJ, Guidugli L, Hansen Tv, Thomassen M, Eccles DM, Tucker K, Benitez J, Domchek SM, Toland AE, Van Rensburg EJ, Wappenschmidt B, Borg Å, Vreeswijk MP, Goldgar DE; ENIGMA Consortium.

J Med Genet. 2012 Aug;49(8):525-32.

18.

A case-control study on risk factors of breast cancer in China.

Xu YL, Sun Q, Shan GL, Zhang J, Liao HB, Li SY, Jiang J, Shao ZM, Jiang HC, Shen NC, Shi Y, Yu CZ, Zhang BN, Chen YH, Duan XN, Li B.

Arch Med Sci. 2012 May 9;8(2):303-9. doi: 10.5114/aoms.2012.28558.

19.

Spatial analysis of county-level breast cancer mortality in Texas.

Bambhroliya AB, Burau KD, Sexton K.

J Environ Public Health. 2012;2012:959343. doi: 10.1155/2012/959343. Epub 2012 Jan 31.

20.

Clinical software development for the Web: lessons learned from the BOADICEA project.

Cunningham AP, Antoniou AC, Easton DF.

BMC Med Inform Decis Mak. 2012 Apr 10;12:30. doi: 10.1186/1472-6947-12-30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk